Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Duvic

Showing results (141-150 of 196) with videos related to

Pageof 20
Sort By:
Clinical and Diagnostic Laboratory Immunology|January 5, 1999
Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphomaB N Lee, M Duvic, C K Tang, et al.
The New England Journal of Medicine|April 8, 1999
Central hypothyroidism associated with retinoid X receptor-selective ligandsS I Sherman, J Gopal, B R Haugen, et al.
Journal of the American Academy of Dermatology|October 1, 1990
Identification of human immunodeficiency virus hybridizing sequences in the peripheral blood of a patient with systemic lupus erythematosusM Blick, J Bresser, J L Lepe-Zuniga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial resultsM Duvic, K Hymes, P Heald, et al.
The Journal of Investigative Dermatology|August 1, 1992
Buschke-Ollendorff syndrome associated with elevated elastin production by affected skin fibroblasts in cultureM G Giro, M Duvic, L T Smith, et al.
Leukemia & Lymphoma|July 31, 1998
Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10D Daliani, R A Ulmer, C Jackow, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 9, 1998
Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory geneD DiSepio, C Ghosn, R L Eckert, et al.
The British Journal of Dermatology|August 3, 2006
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinionC Assaf, M Bagot, R Dummer, et al.
Human Molecular Genetics|July 1, 1994
Localization of the gene whose mutations underlie Hailey-Hailey disease to chromosome 3qS Ikeda, E A Welsh, A M Peluso, et al.
Archives of Dermatology|May 18, 2001
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphomaM Duvic, A G Martin, Y Kim, et al.
Pageof 20

Showing results (141-150 of 196) with videos related to

Sort By:
Pageof 20
Clinical and Diagnostic Laboratory Immunology|January 5, 1999
Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphomaB N Lee, M Duvic, C K Tang, et al.
The New England Journal of Medicine|April 8, 1999
Central hypothyroidism associated with retinoid X receptor-selective ligandsS I Sherman, J Gopal, B R Haugen, et al.
Journal of the American Academy of Dermatology|October 1, 1990
Identification of human immunodeficiency virus hybridizing sequences in the peripheral blood of a patient with systemic lupus erythematosusM Blick, J Bresser, J L Lepe-Zuniga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial resultsM Duvic, K Hymes, P Heald, et al.
The Journal of Investigative Dermatology|August 1, 1992
Buschke-Ollendorff syndrome associated with elevated elastin production by affected skin fibroblasts in cultureM G Giro, M Duvic, L T Smith, et al.
Leukemia & Lymphoma|July 31, 1998
Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10D Daliani, R A Ulmer, C Jackow, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 9, 1998
Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory geneD DiSepio, C Ghosn, R L Eckert, et al.
The British Journal of Dermatology|August 3, 2006
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinionC Assaf, M Bagot, R Dummer, et al.
Human Molecular Genetics|July 1, 1994
Localization of the gene whose mutations underlie Hailey-Hailey disease to chromosome 3qS Ikeda, E A Welsh, A M Peluso, et al.
Archives of Dermatology|May 18, 2001
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphomaM Duvic, A G Martin, Y Kim, et al.
Pageof 20